Nantucket Group

NantWorks is a diversified health and technology conglomerate founded by Dr. Patrick Soon-Shiong. The company operates a vast ecosystem of subsidiaries, including ImmunityBio (formerly NantKwest and NantCell), NantHealth, and NantOmics, focused on integrating molecular diagnostics, genomic sequencing, and immunotherapy to treat cancer and infectious diseases. NantWorks is known for its 'Cancer Moonshot' initiative and its development of novel cell therapies, including natural killer (NK) cell and T-cell based treatments, as well as its comprehensive health information technology platforms. The company's lead asset, Anktiva, was recently approved for the treatment of non-muscle invasive bladder cancer. Nantucket Group, LLC serves as the private holding company and parent entity for the entire NantWorks ecosystem.